Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
CVX enters its October 30 earnings report at $217.73, up nearly 5% on the week, with the stock now within 5% of the mean analyst price target and short sellers continuing to rebuild positions at a pace that has drawn attention without yet reaching a level that changes the fundamental story.
The short interest rebuild documented in Sunday's note has continued. Estimated short interest nudged up another 1.5% on Tuesday to 24.65 million shares, leaving the one-week change at 12.7% and the one-month build at 51%. SI as a percentage of the free float is now 1.22%, a fraction above the 1.3% reading that last week's note flagged as the highest since the March 2026 peak of 1.4%. The pace of accumulation remains the standout, not the absolute level. Borrow availability is completely unconstrained, with the ratio of shares available relative to the short position at the maximum reading, and the cost to borrow, while up 29% on the week to 0.46%, is still near the bottom of any meaningful range. Nothing in the lending market suggests a squeeze setup; the short build looks more like pre-earnings positioning than a structural bet against the company. The options market corroborates that read. The put/call ratio at 0.68 is slightly below its 20-day average of 0.71, meaning options traders as a group are leaning mildly bullish rather than hedging aggressively into the print.
The Street view has been moving in one direction. TD Cowen raised its target again on October 12, this time from $215 to $225 while holding a Hold rating. UBS lifted to $235 from $220 on October 8, keeping its Buy. Those moves follow HSBC's September 25 raise to $250, the most aggressive target on the board. The cluster of upgrades has pushed the mean price target to $228, and the stock at $217.73 now trades within comfortable striking distance of that level. The bull case, as the Street frames it, centres on the portfolio cleanup following the HES acquisition and the completed TCO FGP project. Bulls see capex falling from around $19 billion per year toward $15 billion at the guidance midpoint, with TCO loan repayments and full-rate Australian LNG operations bolstering free cash flow. Bears note that Q3 EPS estimates have been trimmed to $4.64 per share, with a $1.1 billion upstream cut and a $1.5 billion timing headwind offsetting downstream gains. Buyback capacity has also been reduced to $2.5 billion for the quarter. The PE multiple has slipped 0.75 points over the past 30 days to 14.1x, while EV/EBITDA has eased to 6.8x. Factor scores back the constructive read: dividend quality ranks in the 85th percentile, EPS momentum over 30 days ranks in the 78th, and the short score rank at 70 reflects relatively low short pressure by historical standards.
On ownership, the August insider activity is worth noting even though it is now two months old. CEO Michael Wirth exercised options and sold open-market shares on August 14, with net sales of around $61.5 million against a $28 million exercise. The CLO and the President of Downstream both made discretionary sales in the same window. None of these were under a 10b5-1 plan. Net insider selling over the 90 days to late August reached roughly $228.6 million. As a data point it is dated, but it is the most recent signal from management on valuation, and it came with the stock in the low $200s. BlackRock reported a holding of 154.8 million shares as of September 30, adding 10.1 million shares in the period, the largest institutional move in the top-holder list. Berkshire Hathaway's position of 84.4 million shares has been unchanged since June, per last disclosure.
Energy peers had a strong week alongside CVX. COP gained 8.9% and SM rose 9.8%, with XOM up 5.8%. CVX's 4.9% move sits roughly in the middle of the peer group, consistent with a broad energy rally rather than a stock-specific catalyst.
With the October 30 print 16 days away, the question is whether the stock can close the gap to the mean target on the earnings numbers, or whether the trimmed EPS estimates and reduced buyback guidance give the pre-earnings short builders enough ammunition to push back.
See the live data behind this article on ORTEX.
Open CVX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
